MoonLake Immunotherapeutics (MLTX) Free Cash Flow (2021 - 2026)

MoonLake Immunotherapeutics' Free Cash Flow history runs 6 years deep, the most recent figure standing at -$66.3 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 73.64% year-over-year to -$66.3 million in Q1 2026; TTM through Mar 2026 was -$224.2 million, a 59.73% decrease from a year earlier, with the FY2025 full-year figure at -$196.0 million, down 67.4% from the prior year.
• Free Cash Flow eased to -$66.3 million in Q1 2026 per MLTX's latest filing, from -$58.8 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$9.0 million in Q1 2023 and bottomed at -$66.3 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$20.8 million (2022), against an average of -$28.1 million.
• Biggest YoY gain for Free Cash Flow was 67.08% in 2022; the steepest drop was 13074.98% in 2022.
• Year by year, Free Cash Flow stood at -$11.6 million in 2022, then dropped by 6.45% to -$12.3 million in 2023, then sank by 294.11% to -$48.6 million in 2024, then declined by 20.85% to -$58.8 million in 2025, then declined by 12.74% to -$66.3 million in 2026.
• Per Business Quant, the three latest MLTX Free Cash Flow figures stand at -$66.3 million (Q1 2026), -$58.8 million (Q4 2025), and -$44.5 million (Q3 2025).